Logo image of TRMED.OL

THOR MEDICAL ASA (TRMED.OL) Stock Fundamental Analysis

Europe - Euronext Oslo - OSL:TRMED - NO0010597883 - Common Stock

5.15 NOK
+0.33 (+6.85%)
Last: 12/23/2025, 7:00:00 PM
Fundamental Rating

2

Taking everything into account, TRMED scores 2 out of 10 in our fundamental rating. TRMED was compared to 82 industry peers in the Biotechnology industry. The financial health of TRMED is average, but there are quite some concerns on its profitability. TRMED is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TRMED has reported negative net income.
TRMED had a negative operating cash flow in the past year.
In the past 5 years TRMED always reported negative net income.
In the past 5 years TRMED always reported negative operating cash flow.
TRMED.OL Yearly Net Income VS EBIT VS OCF VS FCFTRMED.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

TRMED has a better Return On Assets (-4.73%) than 62.20% of its industry peers.
With a decent Return On Equity value of -5.61%, TRMED is doing good in the industry, outperforming 67.07% of the companies in the same industry.
Industry RankSector Rank
ROA -4.73%
ROE -5.61%
ROIC N/A
ROA(3y)-146.91%
ROA(5y)-131.48%
ROE(3y)-270.57%
ROE(5y)-231.37%
ROIC(3y)N/A
ROIC(5y)N/A
TRMED.OL Yearly ROA, ROE, ROICTRMED.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TRMED so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TRMED.OL Yearly Profit, Operating, Gross MarginsTRMED.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20K -40K -60K -80K -100K

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for TRMED has been increased compared to 1 year ago.
The number of shares outstanding for TRMED has been increased compared to 5 years ago.
The debt/assets ratio for TRMED is higher compared to a year ago.
TRMED.OL Yearly Shares OutstandingTRMED.OL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
TRMED.OL Yearly Total Debt VS Total AssetsTRMED.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 13.17 indicates that TRMED is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 13.17, TRMED belongs to the best of the industry, outperforming 89.02% of the companies in the same industry.
A Debt/Equity ratio of 0.02 indicates that TRMED is not too dependend on debt financing.
The Debt to Equity ratio of TRMED (0.02) is better than 70.73% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 13.17
ROIC/WACCN/A
WACCN/A
TRMED.OL Yearly LT Debt VS Equity VS FCFTRMED.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M 800M

2.3 Liquidity

A Current Ratio of 8.87 indicates that TRMED has no problem at all paying its short term obligations.
TRMED's Current ratio of 8.87 is amongst the best of the industry. TRMED outperforms 91.46% of its industry peers.
TRMED has a Quick Ratio of 8.78. This indicates that TRMED is financially healthy and has no problem in meeting its short term obligations.
TRMED's Quick ratio of 8.78 is amongst the best of the industry. TRMED outperforms 91.46% of its industry peers.
Industry RankSector Rank
Current Ratio 8.87
Quick Ratio 8.78
TRMED.OL Yearly Current Assets VS Current LiabilitesTRMED.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 94.44% over the past year.
EPS 1Y (TTM)94.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-80.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

TRMED is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.39% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y50.51%
EPS Next 2Y34.09%
EPS Next 3Y21.6%
EPS Next 5Y17.39%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TRMED.OL Yearly Revenue VS EstimatesTRMED.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2025 2026 2027 50M 100M 150M
TRMED.OL Yearly EPS VS EstimatesTRMED.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TRMED. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TRMED. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRMED.OL Price Earnings VS Forward Price EarningsTRMED.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, TRMED is valued a bit cheaper than the industry average as 65.85% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 322.85
TRMED.OL Per share dataTRMED.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as TRMED's earnings are expected to grow with 21.60% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.09%
EPS Next 3Y21.6%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TRMED!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

THOR MEDICAL ASA

OSL:TRMED (12/23/2025, 7:00:00 PM)

5.15

+0.33 (+6.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-28 2024-02-28/amc
Earnings (Next)N/A N/A
Inst Owners5.67%
Inst Owner ChangeN/A
Ins Owners2.03%
Ins Owner ChangeN/A
Market Cap1.82B
Revenue(TTM)N/A
Net Income(TTM)-26.56M
Analysts84.44
Price Target5.1 (-0.97%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.85
P/tB 10.66
EV/EBITDA 322.85
EPS(TTM)-0.15
EYN/A
EPS(NY)-0.21
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.13
OCFYN/A
SpS0
BVpS1.34
TBVpS0.48
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -4.73%
ROE -5.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-146.91%
ROA(5y)-131.48%
ROE(3y)-270.57%
ROE(5y)-231.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA 1.53
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.87
Quick Ratio 8.78
Altman-Z 13.17
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)94.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-80.18%
EPS Next Y50.51%
EPS Next 2Y34.09%
EPS Next 3Y21.6%
EPS Next 5Y17.39%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y97.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.22%
EBIT Next 3Y20.09%
EBIT Next 5Y18.8%
FCF growth 1Y81.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y88.7%
OCF growth 3YN/A
OCF growth 5YN/A

THOR MEDICAL ASA / TRMED.OL FAQ

Can you provide the ChartMill fundamental rating for THOR MEDICAL ASA?

ChartMill assigns a fundamental rating of 2 / 10 to TRMED.OL.


What is the valuation status for TRMED stock?

ChartMill assigns a valuation rating of 1 / 10 to THOR MEDICAL ASA (TRMED.OL). This can be considered as Overvalued.


What is the profitability of TRMED stock?

THOR MEDICAL ASA (TRMED.OL) has a profitability rating of 1 / 10.


What is the expected EPS growth for THOR MEDICAL ASA (TRMED.OL) stock?

The Earnings per Share (EPS) of THOR MEDICAL ASA (TRMED.OL) is expected to grow by 50.51% in the next year.